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Harnessing the patient voice in real-world evidence: the essential role of patient-
reported outcomes 
Melanie J. Calvert, Daniel J. O’Connor, Ethan M. Basch. 
Real-world evidence (RWE) is increasingly valued by regulators and payers but importantly 
can also inform meaningful discussions between clinicians and patients regarding the 
treatment experience.   Central to this evidence base is patient-reported outcome (PRO) 
data describing the impact of drugs on quality of life, activities of daily and symptoms.  Here, 
we highlight key challenges with current PRO RWE and describe collaborative next steps for 
international stakeholders to overcome these issues. 
 
Advances in health informatics infrastructure and capabilities for analysing complex large 
datasets bring opportunities to better characterize the experiences of patients during usual 
care.  RWE data sources include electronic health records, insurance claims and billing, 
registries, or on site medical chart review. Often missing from these data sources is 
information about how patients feel and function, as captured directly from patients 
themselves.1 As pressures from legislation, international regulatory authorities, and patient 
groups promote more patient centric drug development and evidence generation,2 attention 
is now turning to the role of PROs to provide the patient perspective in real world datasets.  
 
By definition, PROs represent health status as reported directly by the patient, without 
interpretation by a clinician or anyone else.2 PROs are collected via questionnaires that elicit 
information about symptoms, physical functioning, and/or health-related quality of life. 
Historically, most PRO collection has occurred in prospective randomised clinical trials, to 
inform regulatory decision-making, health technology assessment, reimbursement, and 
clinical practice guidelines.  
 
Current challenges in PRO real-world evidence 
In real world contexts, prospective PRO collection has been limited and fragmented to date, 
with PROs collected in only 14% (n=8/57) of recent post authorization safety studies, 
consisting largely of one-off registries for post-marketing assessment sponsored by drug 
manufacturers in specific populations.1   Secondary sources of real world data such as 
electronic health records and insurance claims often do not capture PROs. Even in rare 
cases when PRO data are collected as a part of routine care delivery, PRO objectives are 
often not clearly defined, the items collected are not consistent across the same patient 
group in different regions and the terminologies and timings of assessments are not 
standardised. This may hinder the integration and interpretation with other data sources, 
resulting in a missed opportunity for learning more about therapeutic interventions and the 
overall patient experience.3  
 
Mandated approaches to PRO collection for audit and benchmarking purposes, such as the 
UK PROMs initiative, have been an important first step in attempting to assess patient-
centred health gain within the NHS. However, to ensure full integration of PROs there is a 
need to improve the efficiency of the data collection,  develop guidance on how best to 
interpret and utilise the data and gain ‘buy in’ from clinicians and patients regarding the 
added value.4 PRO data collected in a real-world setting needs to generate benefits for 
patients and clinicians for broader benefits to be fully realised.3  
 
Without PRO data, RWE will not actually reflect how real patients experience real therapies 
in the real world.  And for these data to be useful, standardization of methods for PRO 
collection, analysis, and reporting is essential - as is availability of standard PRO data 
collection tools.  
Vision and Strategic Priorities 
Our vision is to ensure high quality, systematic collection of real-world PRO data that can 
meaningfully inform patient-centred drug development throughout the product lifecycle.  The 
opportunity to benefit patients, healthcare professionals and society is substantial. In early 
phases of development, real world PRO data can provide evidence of the burden and 
natural history of disease, supporting the selection of the most appropriate primary and 
secondary endpoints for trials. PROs in early access and compassionate use schemes can 
provide additional complementary insights pre-licence to the clinical trial data and help 
protect patient safety with PRO alerts. Post authorization, PROs can offer data on long-term 
tolerability, safety and effectiveness in populations that are more representative than 
preapproval trials, impacting clinical decision-making and guideline development, and 
supporting managed access programs e.g. for novel drugs, such as advanced therapies, 
with high up-front costs but long-term treatment effects, demonstration of the lifetime effects 
of therapy will play an important role in reimbursement. Real world PRO data also offer 
benefits at the individual patient level- offering real-time symptom monitoring and tailoring of 
care to individual patient needs.3,5 
Table 1 shows some key considerations in the design and implementation of PRO programs 
for real world evidence generation, derived from standard approaches in more established 
research contexts such as prospective clinical trials and cohort studies. Implementation can 
be resource intensive, therefore, institutional and ground level support for integration into 
workflow and technology infrastructure and consideration of who pays for data collection are 
essential components for success.  To optimise PRO RWE we consider the following to be 
key strategic priorities: 
 Ensure international collaboration across multiple stakeholders including patients, 
caregivers, clinicians, regulators, ethicists, industry, payers, and policy makers to 
agree a standardised approach to assessment. 
 Develop a comprehensive standard set of recommendations, methods and tools that 
are applicable to PRO RWE generation in different settings. Such recommendations 
should be applicable to both primary data collection in prospective registries and 
secondary data from electronic healthcare records.    
 Formulate a clear governance process for PRO RWE generation including an ethical 
framework for how patients should be consented, who selects patients, who can 
access data and how data will be used.3   
 Establish standard sets of PRO measures, electronic tools, and administration 
schedules to raise the bar; there are ongoing efforts (e.g. FDA exploring a common 
PRO assessment strategy, the European Union Innovative Medicines Initiative (IMI) 
GetReal project).  
 Develop and use electronic PROs wherever possible. 
 Minimize workload and technical complexity for patients, clinicians and health 
providers.  
 Carefully consider the objectives of PRO assessment, the timing of assessments, 
length of follow up, minimization of missingness, and inclusion of patients from 
diverse backgrounds.6  
 Ensure data collection adheres to the FAIR guiding principles for scientific data 
management and stewardship (findable, accessible, interoperable, reusable). 
 Provide guidance on how to interpret and use the data. 
 Ensure patients and clinicians gain value from assessment through real time access 
to PRO data to tailor care to individual needs.3,5 
 
 
 
In summary, PROs represent health status as reported directly by the patient and offer the 
potential to capture how a patient feels and functions during their usual care, providing 
information that is useful to the patient themselves with regards to treatment choices, to the 
healthcare professional and health service provider. Without PRO data, RWE will not reflect 
real treatment experiences and such data should be considered across the whole of drug life 
cycle. However, there is a need for greater standardisation and we have identified a number 
of key considerations in the design and implementation of PRO programs for RWE 
generation. Incorporation of RWE in regulatory decisions, clinical practice guidelines, and 
health policy is still nascent. But as momentum increases and aggregated clinical data 
become increasingly available for RWE, attention should turn to increasing international 
collaboration, developing the required tool kit and consistently complementing these real 
world data with PROs.  
 
 
  
Table 1: Key design considerations for collecting patient-reported outcomes for real world 
evidence generation 
Design element Considerations 
Objectives 
 
Clear objectives should be determined as to why PRO data are being 
collected. This should be informed by existing evidence where available 
(e.g. evidence from trials, meta-analyses or RWD) 
 
Patient 
population 
Patient population should be defined by inclusion - exclusion criteria 
 
Instrument 
selection / tool 
box 
 
The questionnaire(s) used to collect the data should be relevant and 
valid for the objectives, and the population of interest and meet 
stakeholder needs. Questionnaires should have been developed with 
patient input.  Language availability, patient acceptability/burden, 
permissions and fee for use should also be considered.  
 
Frequency of 
administration 
Frequency will depend on stakeholder needs and the study population.  
Patients with high symptom burden may require more frequent 
monitoring. 
 
Mode of 
administration 
The data collection plan should outline the permitted modes of 
administration (e.g. paper, telephone, electronic, other).  
 
Data collection 
method / source 
data 
 
Consider primary or secondary collection. Feasibility and resources to 
support data collection, existing registries, electronic health records, 
requirement for bespoke collection.  Specify management strategies to 
minimise missing data and bias. Methods to ensure quality control. IT 
infrastructure may be based on existing system or customised / 
commercial products. 
 
Monitoring of 
data 
Whether PRO data will be monitored and used to directly inform patient 
care.5,6 
Presentation of 
results 
The data should be analysed and reported appropriate, in accordance 
with the prospective described objectives and the instrument 
recommendations, leading to robust conclusions considering potential 
sources of bias / confounding. 
 
 
Ethics 
 
The requirement for ethics approvals should be consider early in the 
proposals for data collection, following engagement with the health 
authorities 
 
Data ownership 
and consent 
 
Contact and agree with health authorities / registry owners 
 
Audit  Mechanisms for on-going audit of data quality etc should be considered 
 
Privacy 
 
Safe guarding privacy and confidentiality of the data 
Clinician 
feedback  
Consider the need for PRO alerts, mechanism to feedback concerning 
results with potential to integrate into patient management pathway 
 
Patient feedback Consider if patients will be able to review PRO results and use these 
data to actively participate in decisions regarding their care. 
 
Healthcare 
provider 
feedback 
Potential to integrate into managed access programmes, etc 
Drug 
manufacturer 
feedback 
Flag to manufacture emerging trends on tolerability and effectiveness in 
different populations 
Regulatory 
authority 
feedback 
Support safety reporting, post authorisation marketing commitments, 
long-term activity data  
Resources Determine who pays for license fees, training, data collection, clinic 
time, device costs etc 
 
Refs 2-6 
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